HiringNot enough data
We need a relevant verified event before scoring this dimension.
EB
Genomics Technology · San Diego, California, USA
Element Biosciences
Current work outlook
Element Biosciences announced an upsized Series E including $175 million from Samsung Electronics plus an undisclosed amount from other investors. The company plans to commercialize new genomic and multiomic products, expand globally and advance research, clinical and diagnostic applications.
Updated June 9, 2026 · Evidence from public sources
Flags outlook69/ 100Positive
1 verified signal in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityNot enough data
We need a relevant verified event before scoring this dimension.
Financial healthNot enough data
We need a relevant verified event before scoring this dimension.
InnovationNot enough data
We need a relevant verified event before scoring this dimension.
What moved the outlook
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Element Biosciences adds at least $175M to accelerate global product expansion
Element Biosciences announced an upsized Series E including $175 million from Samsung Electronics plus an undisclosed amount from other investors. The company plans to commercialize new genomic and multiomic products, expand globally and advance research, clinical and diagnostic applications.
Employee impact
Read full analysis →The financing is a positive signal for candidates in scientific software, bioinformatics, instrument engineering, product development and commercialization. Funding supports several product launches, but applicants should confirm which programs have committed staffing and how regulatory or launch delays could affect their role.